It was not, therefore appropriate to retain Alba Bioscienceas part of NHS Scotland, with responsibility for investment and associated risksinvolved.The sale will haveno impact on the provision of medical products used in the treatment of patients.There are a number of alternative suppliers of the products that NHS Scotland requires,which will continue to be procured under existing arrangements in the same way thatmost modern pharmaceutical products are bought by the NHS.The sale has providedstability for the vast majority of staff, who have transferred...